Atea Pharmaceuticals, Inc.
AVIR
$4.49
$0.143.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 45.09% | 125.03% | 88.41% | 39.40% | -50.76% |
| Gross Profit | -45.09% | -125.03% | -88.41% | -39.40% | 50.76% |
| SG&A Expenses | -27.31% | -46.72% | -34.62% | -25.78% | -22.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.98% | 58.56% | 45.05% | 16.92% | -45.84% |
| Operating Income | -26.98% | -58.56% | -45.05% | -16.92% | 45.84% |
| Income Before Tax | -33.23% | -54.98% | -35.34% | 8.25% | 45.87% |
| Income Tax Expenses | -75.37% | -3,108.00% | -13.27% | -14.81% | -12.12% |
| Earnings from Continuing Operations | -32.59% | -33.76% | -34.98% | 8.29% | 45.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.59% | -33.76% | -34.98% | 8.29% | 45.75% |
| EBIT | -26.98% | -58.56% | -45.05% | -16.92% | 45.84% |
| EBITDA | -27.06% | -58.74% | -45.20% | -16.97% | 45.91% |
| EPS Basic | -42.59% | -44.62% | -44.15% | 7.75% | 46.55% |
| Normalized Basic EPS | -48.63% | -93.01% | -77.90% | -29.40% | 48.59% |
| EPS Diluted | -42.59% | -44.62% | -44.15% | 7.75% | 46.55% |
| Normalized Diluted EPS | -48.63% | -93.01% | -77.90% | -29.40% | 48.59% |
| Average Basic Shares Outstanding | -7.00% | -7.50% | -6.36% | -0.60% | 1.48% |
| Average Diluted Shares Outstanding | -7.00% | -7.50% | -6.36% | -0.60% | 1.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |